Full CoverageAmgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
By Elaine Chen
Top news
Monthly weight loss drug helps people lose 20% of body weight, trial finds
By Berkeley Lovelace Jr.
ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half
By Elizabeth Eaton
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
By Josh Nathan-kazis
All coverage
Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment
By Anjalee Khemlani
New once-a-month drug could treat diabetes and obesity, scientists say
By Vishwam Sankaran
The 'Very Tough' Obesity Meeting That Hammered Amgen Stock
By Allison Gatlin
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
By Henry Khederian
Spotlight On: Five ways MariTide's dosing, tolerability could keep it buoyant in competitive waters
By Jessica D'Amico